Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Notes Payables (2019 - 2025)

Bioadaptives' Notes Payables history spans 7 years, with the latest figure at $32096.0 for Q3 2025.

  • For Q3 2025, Notes Payables changed 0.0% year-over-year to $32096.0; the TTM value through Sep 2025 reached $32096.0, changed 0.0%, while the annual FY2024 figure was $32096.0, N/A changed from the prior year.
  • Notes Payables for Q3 2025 was $32096.0 at Bioadaptives, down from $311000.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $479284.0 in Q2 2021 and bottomed at $10246.0 in Q3 2022.
  • The 5-year median for Notes Payables is $312551.5 (2024), against an average of $252329.4.
  • The largest annual shift saw Notes Payables surged 3078.52% in 2023 before it crashed 90.14% in 2024.
  • A 5-year view of Notes Payables shows it stood at $403117.0 in 2021, then dropped by 5.29% to $381793.0 in 2022, then dropped by 14.7% to $325671.0 in 2023, then plummeted by 90.14% to $32096.0 in 2024, then changed by 0.0% to $32096.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Notes Payables are $32096.0 (Q3 2025), $311000.0 (Q2 2025), and $311000.0 (Q1 2025).